Subcutaneous Fat Distribution is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer

Jong Soo Lee, Hye Sun Lee, Jee Soo Ha, Kyung Suk Han, Koon Ho Rha, Sung Joon Hong, Byung Ha Chung, Kyo Chul Koo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: The relationship between body fat distribution and survival remains unclear in patients with castration resistant prostate cancer treated with docetaxel and androgen receptor axis targeted agents. We investigated whether body composition parameters could predict radiographic progression-free and cancer specific survival in patients with castration resistant prostate cancer. Materials and Methods: In this multicenter retrospective study we evaluated data on 282 consecutive patients diagnosed with castration resistant prostate cancer between September 2009 and March 2017. The subcutaneous fat index, the visceral fat index and the skeletal muscle index at the diagnosis of castration resistant prostate cancer were determined by computerized tomography data. Survival analyses were performed using the subcutaneous fat, visceral fat and skeletal muscle indexes dichotomized at 39.9, 58 and 52.4 cm 2 /m 2 , respectively. Results: At the diagnosis of castration resistant prostate cancer, cancer specific survival was independently predicted using prostate specific antigen levels, Gleason score 8 or greater, performance status, a shorter interval from androgen deprivation therapy to castration resistant prostate cancer and a subcutaneous fat index of less than 39.9 cm 2 /m 2 . During the median followup of 16.0 months patients with a subcutaneous fat index of 39.9 cm 2 /m 2 or greater received more docetaxel cycles than patients with a subcutaneous fat index of less than 39.9 cm 2 /m 2 . Compared to patients with a subcutaneous fat index of less than 39.9 cm 2 /m 2 those with an index of 39.9 cm 2 /m 2 or greater had better 1-year progression-free and 2-year cancer specific survival (p = 0.009 and 0.021, respectively). Conclusions: Patients with a subcutaneous fat index of 39.9 cm 2 /m 2 or greater at the diagnosis of castration resistant prostate cancer showed higher progression-free and cancer specific survival rates than those with a subcutaneous fat index of less 39.9 cm 2 /m 2 at diagnosis. The subcutaneous fat index determined by computerized tomography data could serve as a useful objective prognostic factor to discuss patient therapeutic options. Further studies are needed to define the roles of each body composition parameter in relation to pharmacokinetics and oncologic outcome.

Original languageEnglish
Pages (from-to)114-120
Number of pages7
JournalJournal of Urology
Volume200
Issue number1
DOIs
Publication statusPublished - 2018 Jul

Fingerprint

Subcutaneous Fat
Castration
Prostatic Neoplasms
Biomarkers
docetaxel
Survival
Intra-Abdominal Fat
Body Composition
Neoplasms
Skeletal Muscle
Tomography
Body Fat Distribution
Neoplasm Grading
Androgen Receptors
Prostate-Specific Antigen
Survival Analysis
Androgens
Multicenter Studies
Survival Rate
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Lee, Jong Soo ; Lee, Hye Sun ; Ha, Jee Soo ; Han, Kyung Suk ; Rha, Koon Ho ; Hong, Sung Joon ; Chung, Byung Ha ; Koo, Kyo Chul. / Subcutaneous Fat Distribution is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer. In: Journal of Urology. 2018 ; Vol. 200, No. 1. pp. 114-120.
@article{596968baf7cf45f882bb3c4dfdb09d50,
title = "Subcutaneous Fat Distribution is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer",
abstract = "Purpose: The relationship between body fat distribution and survival remains unclear in patients with castration resistant prostate cancer treated with docetaxel and androgen receptor axis targeted agents. We investigated whether body composition parameters could predict radiographic progression-free and cancer specific survival in patients with castration resistant prostate cancer. Materials and Methods: In this multicenter retrospective study we evaluated data on 282 consecutive patients diagnosed with castration resistant prostate cancer between September 2009 and March 2017. The subcutaneous fat index, the visceral fat index and the skeletal muscle index at the diagnosis of castration resistant prostate cancer were determined by computerized tomography data. Survival analyses were performed using the subcutaneous fat, visceral fat and skeletal muscle indexes dichotomized at 39.9, 58 and 52.4 cm 2 /m 2 , respectively. Results: At the diagnosis of castration resistant prostate cancer, cancer specific survival was independently predicted using prostate specific antigen levels, Gleason score 8 or greater, performance status, a shorter interval from androgen deprivation therapy to castration resistant prostate cancer and a subcutaneous fat index of less than 39.9 cm 2 /m 2 . During the median followup of 16.0 months patients with a subcutaneous fat index of 39.9 cm 2 /m 2 or greater received more docetaxel cycles than patients with a subcutaneous fat index of less than 39.9 cm 2 /m 2 . Compared to patients with a subcutaneous fat index of less than 39.9 cm 2 /m 2 those with an index of 39.9 cm 2 /m 2 or greater had better 1-year progression-free and 2-year cancer specific survival (p = 0.009 and 0.021, respectively). Conclusions: Patients with a subcutaneous fat index of 39.9 cm 2 /m 2 or greater at the diagnosis of castration resistant prostate cancer showed higher progression-free and cancer specific survival rates than those with a subcutaneous fat index of less 39.9 cm 2 /m 2 at diagnosis. The subcutaneous fat index determined by computerized tomography data could serve as a useful objective prognostic factor to discuss patient therapeutic options. Further studies are needed to define the roles of each body composition parameter in relation to pharmacokinetics and oncologic outcome.",
author = "Lee, {Jong Soo} and Lee, {Hye Sun} and Ha, {Jee Soo} and Han, {Kyung Suk} and Rha, {Koon Ho} and Hong, {Sung Joon} and Chung, {Byung Ha} and Koo, {Kyo Chul}",
year = "2018",
month = "7",
doi = "10.1016/j.juro.2018.01.069",
language = "English",
volume = "200",
pages = "114--120",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

Subcutaneous Fat Distribution is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer. / Lee, Jong Soo; Lee, Hye Sun; Ha, Jee Soo; Han, Kyung Suk; Rha, Koon Ho; Hong, Sung Joon; Chung, Byung Ha; Koo, Kyo Chul.

In: Journal of Urology, Vol. 200, No. 1, 07.2018, p. 114-120.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Subcutaneous Fat Distribution is a Prognostic Biomarker for Men with Castration Resistant Prostate Cancer

AU - Lee, Jong Soo

AU - Lee, Hye Sun

AU - Ha, Jee Soo

AU - Han, Kyung Suk

AU - Rha, Koon Ho

AU - Hong, Sung Joon

AU - Chung, Byung Ha

AU - Koo, Kyo Chul

PY - 2018/7

Y1 - 2018/7

N2 - Purpose: The relationship between body fat distribution and survival remains unclear in patients with castration resistant prostate cancer treated with docetaxel and androgen receptor axis targeted agents. We investigated whether body composition parameters could predict radiographic progression-free and cancer specific survival in patients with castration resistant prostate cancer. Materials and Methods: In this multicenter retrospective study we evaluated data on 282 consecutive patients diagnosed with castration resistant prostate cancer between September 2009 and March 2017. The subcutaneous fat index, the visceral fat index and the skeletal muscle index at the diagnosis of castration resistant prostate cancer were determined by computerized tomography data. Survival analyses were performed using the subcutaneous fat, visceral fat and skeletal muscle indexes dichotomized at 39.9, 58 and 52.4 cm 2 /m 2 , respectively. Results: At the diagnosis of castration resistant prostate cancer, cancer specific survival was independently predicted using prostate specific antigen levels, Gleason score 8 or greater, performance status, a shorter interval from androgen deprivation therapy to castration resistant prostate cancer and a subcutaneous fat index of less than 39.9 cm 2 /m 2 . During the median followup of 16.0 months patients with a subcutaneous fat index of 39.9 cm 2 /m 2 or greater received more docetaxel cycles than patients with a subcutaneous fat index of less than 39.9 cm 2 /m 2 . Compared to patients with a subcutaneous fat index of less than 39.9 cm 2 /m 2 those with an index of 39.9 cm 2 /m 2 or greater had better 1-year progression-free and 2-year cancer specific survival (p = 0.009 and 0.021, respectively). Conclusions: Patients with a subcutaneous fat index of 39.9 cm 2 /m 2 or greater at the diagnosis of castration resistant prostate cancer showed higher progression-free and cancer specific survival rates than those with a subcutaneous fat index of less 39.9 cm 2 /m 2 at diagnosis. The subcutaneous fat index determined by computerized tomography data could serve as a useful objective prognostic factor to discuss patient therapeutic options. Further studies are needed to define the roles of each body composition parameter in relation to pharmacokinetics and oncologic outcome.

AB - Purpose: The relationship between body fat distribution and survival remains unclear in patients with castration resistant prostate cancer treated with docetaxel and androgen receptor axis targeted agents. We investigated whether body composition parameters could predict radiographic progression-free and cancer specific survival in patients with castration resistant prostate cancer. Materials and Methods: In this multicenter retrospective study we evaluated data on 282 consecutive patients diagnosed with castration resistant prostate cancer between September 2009 and March 2017. The subcutaneous fat index, the visceral fat index and the skeletal muscle index at the diagnosis of castration resistant prostate cancer were determined by computerized tomography data. Survival analyses were performed using the subcutaneous fat, visceral fat and skeletal muscle indexes dichotomized at 39.9, 58 and 52.4 cm 2 /m 2 , respectively. Results: At the diagnosis of castration resistant prostate cancer, cancer specific survival was independently predicted using prostate specific antigen levels, Gleason score 8 or greater, performance status, a shorter interval from androgen deprivation therapy to castration resistant prostate cancer and a subcutaneous fat index of less than 39.9 cm 2 /m 2 . During the median followup of 16.0 months patients with a subcutaneous fat index of 39.9 cm 2 /m 2 or greater received more docetaxel cycles than patients with a subcutaneous fat index of less than 39.9 cm 2 /m 2 . Compared to patients with a subcutaneous fat index of less than 39.9 cm 2 /m 2 those with an index of 39.9 cm 2 /m 2 or greater had better 1-year progression-free and 2-year cancer specific survival (p = 0.009 and 0.021, respectively). Conclusions: Patients with a subcutaneous fat index of 39.9 cm 2 /m 2 or greater at the diagnosis of castration resistant prostate cancer showed higher progression-free and cancer specific survival rates than those with a subcutaneous fat index of less 39.9 cm 2 /m 2 at diagnosis. The subcutaneous fat index determined by computerized tomography data could serve as a useful objective prognostic factor to discuss patient therapeutic options. Further studies are needed to define the roles of each body composition parameter in relation to pharmacokinetics and oncologic outcome.

UR - http://www.scopus.com/inward/record.url?scp=85047099410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047099410&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2018.01.069

DO - 10.1016/j.juro.2018.01.069

M3 - Article

C2 - 29366641

AN - SCOPUS:85047099410

VL - 200

SP - 114

EP - 120

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -